Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONDUCT: Duodart vs Watchful Waiting in BPH
NCT01294592Phase 4Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial of dutasteride in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Primary endpoint: International Prostate Symptom Score at 24 months. Started Dec 2010; status: completed.
02
Drugs
dutasteride
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01294592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294592.